Cetera Advisor Networks LLC Alnylam Pharmaceuticals, Inc. Transaction History

Cetera Advisor Networks LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$151.41 - $196.57 $28,010 - $36,365	-185 Reduced 13.17%	1,220 $233,000
Q3 2023 Nov 14, 2023	SELL	$170.77 - $211.65 $13,149 - $16,297	-77 Reduced 5.2%	1,405 $248,000
Q2 2023 Aug 09, 2023	SELL	$185.01 - $212.05 $30,526 - $34,988	-165 Reduced 10.02%	1,482 $281,000
Q1 2023 May 15, 2023	BUY	$182.66 - $235.53 $1,643 - $2,119	9 Added 0.55%	1,647 $329,000
Q4 2022 Feb 14, 2023	BUY	$185.53 - $241.31 $303,898 - $395,265	1,638 New	1,638 $389,000
Q2 2022 Aug 11, 2022	BUY	$120.42 - $169.29 $66,712 - $93,786	554 Added 12.89%	4,853 $708,000
Q1 2022 May 12, 2022	BUY	$127.18 - $173.91 $166,987 - $228,343	1,313 Added 43.97%	4,299 $702,000
Q4 2021 Feb 14, 2022	BUY	$159.56 - $209.29 $35,901 - $47,090	225 Added 8.15%	2,986 $506,000
Q3 2021 Nov 16, 2021	BUY	$169.75 - $207.73 $118,146 - $144,580	696 Added 33.7%	2,761 $521,000
Q2 2021 Aug 13, 2021	BUY	$128.63 - $176.89 $265,620 - $365,277	2,065 New	2,065 $350,000

644

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $28.8B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Cetera Advisor Networks LLC, based on Form 13F filings with the SEC.

Stay updated on Cetera Advisor Networks LLC with notifications on news.